Evidence map›Paper›PMID 28326343›Full record

ArticleBone reports2016

Tomoharu Takeuchi, Moyuko Nagasaka, Miyuki Shimizu, Mayumi Tamura, Yoichiro Arata

Open access · goldAbstract read
In one paragraph

Article in Bone reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Regulation of Nuclear Factor-kappaB Function byFrontiers in cell and developmental biology · 2021
    Review
  9. Immunomodulatory Effects ofMarine drugs · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tomoharu TakeuchiFaculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Moyuko NagasakaFaculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Miyuki ShimizuFaculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Mayumi TamuraFaculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Yoichiro ArataFaculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
Josai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoclasts are the only cells in an organism capable of resorbing bone. These cells differentiate from monocyte/macrophage lineage cells upon stimulation by receptor activator of NF-κB ligand (RANKL). On the other hand, osteoclastogenesis is reportedly suppressed by glucose via the downregulation of NF-κB activity through suppression of reactive oxygen species generation. To examine whether other sugars might also affect osteoclast development, we compared the effects of monomeric sugars (glucose, galactose,

Indexed as

Gal, galactoseGalNAc, N-acetylgalactosamineGlc, glucoseGlcNAcGlcNAc, N-acetylglucosamineM-CSF, macrophage colony-stimulating factorN-acetylglucosamineNF-κBNF-κB, nuclear factor-κBO-GlcNAcylationOsteoclastPBMC, peripheral blood mononuclear cellPUGNAc, O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenylcarbamateRANKL, receptor activator of nuclear factor-κB ligandROS, reactive oxygen speciessRANKL, soluble receptor activator of nuclear factor-κB ligandTRAP, tartrate-resistant acid phosphataseUDP, uridine diphosphate

Identifiers

PMID28326343
PMCPMC4926832
OpenAlexW2254543389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.